Evaluation of 2 Commercially Systems for Detection of Serum Squamous Cell Carcinoma Antigen in Pan Squamous Cell Carcinoma

Overview

Journal Cancer Control

Specialty Oncology

Date 2020 Dec 28

PMID 33356502

Citations 4

Authors

Hao Chen

Liru Tian

Jiahong Chen

Peng Sun

Runkun Han

Xingping Wu

Shuqin Dai

Affiliations

Soon will be listed here.

Abstract

Background: This study compared the analytical performance of the Elecsys 602 (Roche Diagnostics) system with the I2000 (Abbott laboratories) system for the quantitative measurement of squamous cell carcinoma antigen (SCCA) to assess its role as an indicator in pan squamous cell carcinoma.

Methods: 435 serum samples included pan squamous cell cancer group (n = 318) and healthy subjects (n = 52) and non-squamous cell group (n = 41) and benign diseases group (n = 24) were measured by 2 systems and compared.

Results: The within-run precision coefficient of variation (CV) for Abbott and Roche systems were 3.34-4.88% and 0.95 -1.96%, and the total precision CV were 2.89-9.48% and 3.97-5.38%, respectively. Good correlation was showed in Abbott and Roche systems (slopes = 0.749, r = 0.9658). Serum SCCA in the groups of nasopharyngeal carcinomas, lung squamous cell carcinoma, esophageal squamous cell carcinoma, bladder cancer and cervical squamous cell carcinoma under the curve area (AUC) was more than 0.5, while the AUC in the non- nasopharyngeal carcinomas head and neck squamous cell carcinoma was less than 0.5. The AUC of 2 systems was statistically different in lung squamous cell carcinoma and nasopharyngeal carcinomas (P < 0.05). The levels of SCCA of 2 systems were similarities in esophageal squamous cell carcinoma(stage IV vs. stage 0a-II)and bladder cancer(stage I vs. stage Oa)and cervical squamous cell carcinoma(stage IIB-III vs. stage I-IIA), which advanced stage had higher level of SCCA than early stage. But the SCCA levels of 2 systems were inconsistent in bladder cancer (stage II-IV vs. stage Oa in Abbott), head and neck squamous cell carcinoma (stage IV vs. stage Oa-I in the Roche) and lung squamous cell carcinoma (stage III vs. stage I-II in the Roche). (P < 0.05).

Conclusions: 2 systems correlated well in SCCA detection of squamous cell carcinoma, but there were individual differences. Serum SCCA may also contribute to the diagnosis of bladder cancer.

Citing Articles

Carboplatin combined with arsenic trioxide versus carboplatin combined with docetaxel treatment for LACC: A randomized, open-label, phase II clinical study.

Li S, Zhang Y, Li H, He Z, Li A, Yan J Open Med (Wars). 2024; 19(1):20241106.

PMID: 39669373 PMC: 11635763. DOI: 10.1515/med-2024-1106.

Improvement and prognosis analysis of nimotuzumab combined with TP regimen induction chemotherapy and sequential concurrent chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma.

Luan W, Yuan H, Hou W, Li J, Liu L Am J Transl Res. 2022; 14(8):5630-5640.

PMID: 36105032 PMC: 9452316.

Assessment of Specific Tumoral Markers, Inflammatory Status, and Vitamin D Metabolism before and after the First Chemotherapy Cycle in Patients with Lung Cancer.

Crintea A, Drugan C, Constantin A, Lupan I, Fekete Z, Silaghi C Biology (Basel). 2022; 11(7).

PMID: 36101414 PMC: 9312139. DOI: 10.3390/biology11071033.

Squamous Cell Carcinoma Antigen: Clinical Application and Research Status.

Zhu H Diagnostics (Basel). 2022; 12(5).

PMID: 35626221 PMC: 9139199. DOI: 10.3390/diagnostics12051065.

References

Imai R, Takenaka Y, Yasui T, Nakahara S, Yamamoto Y, Hanamoto A . Prognostic significance of serum squamous cell carcinoma antigen in patients with head and neck cancer. Acta Otolaryngol. 2015; 135(3):295-301. DOI: 10.3109/00016489.2014.951454. View

Franek M . Structural aspects of steroid-antibody specificity. J Steroid Biochem. 1987; 28(1):95-108. DOI: 10.1016/0022-4731(87)90130-0. View

Kosugi S, Nishimaki T, Kanda T, Nakagawa S, Ohashi M, Hatakeyama K . Clinical significance of serum carcinoembryonic antigen, carbohydrate antigen 19-9, and squamous cell carcinoma antigen levels in esophageal cancer patients. World J Surg. 2004; 28(7):680-5. DOI: 10.1007/s00268-004-6865-y. View

Sturgeon C, Duffy M, Hofmann B, Lamerz R, Fritsche H, Gaarenstroom K . National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem. 2010; 56(6):e1-48. DOI: 10.1373/clinchem.2009.133124. View

Snyderman C, DAmico F, Wagner R, Eibling D . A reappraisal of the squamous cell carcinoma antigen as a tumor marker in head and neck cancer. Arch Otolaryngol Head Neck Surg. 1995; 121(11):1294-7. DOI: 10.1001/archotol.1995.01890110068012. View

OConnor T, Gosling J . The dependence of radioimmunoassay detection limits on antibody affinity. J Immunol Methods. 1998; 208(2):181-9. DOI: 10.1016/s0022-1759(97)00148-8. View

Molina R, Filella X, Torres M, Ballesta A, Mengual P, Cases A . SCC antigen measured in malignant and nonmalignant diseases. Clin Chem. 1990; 36(2):251-4. View

Izuhara K, Ohta S, Kanaji S, Shiraishi H, Arima K . Recent progress in understanding the diversity of the human ov-serpin/clade B serpin family. Cell Mol Life Sci. 2008; 65(16):2541-53. PMC: 11131704. DOI: 10.1007/s00018-008-8049-7. View

Passerini R, Cassatella M, Boveri S, Salvatici M, Radice D, Zorzino L . The pitfalls of CA19-9: routine testing and comparison of two automated immunoassays in a reference oncology center. Am J Clin Pathol. 2012; 138(2):281-7. DOI: 10.1309/AJCPOPNPLLCYR07H. View

10.

Zhao W, Yu H, Han Z, Gao N, Xue J, Wang Y . Clinical significance of joint detection of serum CEA, SCCA, and bFGF in the diagnosis of lung cancer. Int J Clin Exp Pathol. 2015; 8(8):9506-11. PMC: 4583944. View

11.

Yasumatsu R, Nakano T, Hashimoto K, Kogo R, Wakasaki T, Nakagawa T . The clinical value of serum squamous cell carcinoma antigens 1 and 2 in head and neck squamous cell carcinoma. Auris Nasus Larynx. 2018; 46(1):135-140. DOI: 10.1016/j.anl.2018.07.010. View

12.

Yoon S, Shin K, Kim J, Seo S, Park S, Kang S . The clinical values of squamous cell carcinoma antigen and carcinoembryonic antigen in patients with cervical cancer treated with concurrent chemoradiotherapy. Int J Gynecol Cancer. 2007; 17(4):872-8. DOI: 10.1111/j.1525-1438.2007.00878.x. View

13.

Gadducci A, Tana R, Cosio S, Genazzani A . The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature. Crit Rev Oncol Hematol. 2007; 66(1):10-20. DOI: 10.1016/j.critrevonc.2007.09.002. View

14.

Ehdaie B, Maschino A, Shariat S, Rioja J, Hamilton R, Lowrance W . Comparative outcomes of pure squamous cell carcinoma and urothelial carcinoma with squamous differentiation in patients treated with radical cystectomy. J Urol. 2011; 187(1):74-9. PMC: 3692007. DOI: 10.1016/j.juro.2011.09.056. View

15.

Barak V, Meirovitz A, Leibovici V, Rachmut J, Peretz T, Eliashar R . The Diagnostic and Prognostic Value of Tumor Markers (CEA, SCC, CYFRA 21-1, TPS) in Head and Neck Cancer Patients. Anticancer Res. 2015; 35(10):5519-24. View

16.

Izuhara K, Yamaguchi Y, Ohta S, Nunomura S, Nanri Y, Azuma Y . Squamous Cell Carcinoma Antigen 2 (SCCA2, SERPINB4): An Emerging Biomarker for Skin Inflammatory Diseases. Int J Mol Sci. 2018; 19(4). PMC: 5979376. DOI: 10.3390/ijms19041102. View

17.

Holdenrieder S, Molina R, Qiu L, Zhi X, Rutz S, Engel C . Technical and clinical performance of a new assay to detect squamous cell carcinoma antigen levels for the differential diagnosis of cervical, lung, and head and neck cancer. Tumour Biol. 2018; 40(4):1010428318772202. DOI: 10.1177/1010428318772202. View

18.

Nakamura T, Ide H, Eguchi R, Hayashi K, Takasaki K, Watanabe S . CYFRA 21-1 as a tumor marker for squamous cell carcinoma of the esophagus. Dis Esophagus. 2017; 11(1):35-39. DOI: 10.1093/dote/11.1.35. View

19.

de Bruijn H, Duk J, van der Zee A, Pras E, Willemse P, Boonstra H . The clinical value of squamous cell carcinoma antigen in cancer of the uterine cervix. Tumour Biol. 1998; 19(6):505-16. DOI: 10.1159/000030044. View

20.

Markovina S, Wang S, Henke L, Luke C, Pak S, DeWees T . Serum squamous cell carcinoma antigen as an early indicator of response during therapy of cervical cancer. Br J Cancer. 2017; 118(1):72-78. PMC: 5765231. DOI: 10.1038/bjc.2017.390. View